A Phase 2 interventional study of cetuximab, cisplatin and cisplatin in Breast Neoplasm, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 46 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cetuximab in Breast Neoplasms — none open to participants now, 2 under way, none of them phase 3. Cetuximab · Breast Neoplasms.
Among the 11 studies testing cetuximab in Breast Neoplasms, this one has the largest enrollment, is the only one that started in 2007, is one of 8 in phase 2, and was the 5th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 11 studies testing cetuximab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 37 across the 11 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 8 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing cetuximab in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab and cisplatin was above a pre-specified threshold of 0.2 in the treatment of "triple negative" metastatic breast cancer.
The secondary objective of this study is to compare the differences between the two treatment groups using the following criteria : Progression-Free Survival (PFS) Time, Overall Survival (OS), Time to Response (TTR) and Safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: cetuximab, cisplatin
Drug: cisplatin
Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion. Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles. Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent.
Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles. Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles. Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent.
Best Overall Response (BOR)
Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Progression-Free Survival (PFS) Time
The PFS was defined as the duration from randomization until radiological progression according to investigator (based on RECIST) or death due to any cause. Only deaths within 85 days of last tumor assessment were considered. Participants without event were censored on the date of last tumor assessment.
Time frame: Time from randomization to disease progression, death or last tumour assessment, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Overall Survival (OS) Time
The OS time was defined as the time from randomization to death. Participants without event were censored at the last date known to be alive or at the clinical cut-off date, whatever was earlier.
Time frame: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 20 June 2007, until cut-off date, 05 April 2010
Time to Response (TTR)
The TTR was determined for participants whose confirmed BOR (based on RECIST) was either a CR or a PR . It was defined as the time from the first dose study treatment until the date of the first assessment of confirmed CR or PR.
Time frame: Time from the first dose of study treatment (cetuximab or cisplatin) to first assessment of CR or PR, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Safety- Number of Participants Experiencing Any Adverse Event (AE)
Number of participants experiencing any AE. AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications.
Time frame: Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010
| Milestone | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Started | 115 | 58 |
| Treated | 114 | 57 |
| Completed | 6 | 4 |
| Not completed | 109 | 54 |
| Withdrew: Progressive disease | 86 | 42 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Death | 4 | 3 |
| Withdrew: Symptomatic deterioration | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 3 | 0 |
| Withdrew: Randomized but not treated | 1 | 1 |
Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
| percentage of participants | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Best Overall Response (BOR) | 20.0 (13.1 to 28.5) | 10.3 (3.9 to 21.2) |
The PFS was defined as the duration from randomization until radiological progression according to investigator (based on RECIST) or death due to any cause. Only deaths within 85 days of last tumor assessment were considered. Participants without event were censored on the date of last tumor assessment.
| months | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Progression-Free Survival (PFS) Time | 3.7 (2.8 to 4.3) | 1.5 (1.4 to 2.8) |
The OS time was defined as the time from randomization to death. Participants without event were censored at the last date known to be alive or at the clinical cut-off date, whatever was earlier.
| months | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Overall Survival (OS) Time | 12.9 (9.6 to 15.6) | 9.4 (6.7 to 14.2) |
The TTR was determined for participants whose confirmed BOR (based on RECIST) was either a CR or a PR . It was defined as the time from the first dose study treatment until the date of the first assessment of confirmed CR or PR.
| months | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Time to Response (TTR) | 1.4 (1.3 to 1.4) | 1.3 (1.2 to 1.4) |
Number of participants experiencing any AE. AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications.
| participants | Cisplatin and Cetuximab | Cisplatin |
|---|---|---|
| Safety- Number of Participants Experiencing Any Adverse Event (AE) | 114 | 57 |
Collected over Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cisplatin and Cetuximab | — | 41/114 (36%) | 112/114 (98.2%) |
| Cisplatin | — | 13/57 (22.8%) | 55/57 (96.5%) |
| Cisplatin Alone Switched to Cetuximab | — | 6/31 (19.4%) | 28/31 (90.3%) |
| Event | Cisplatin and Cetuximab | Cisplatin | Cisplatin Alone Switched to Cetuximab |
|---|---|---|---|
| General Physical Health DeteriorationGeneral disorders | 4/114 | 1/57 | 2/31 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 4/114 | 0/57 | 2/31 |
| DyspnoaeRespiratory, thoracic and mediastinal disorders | 6/114 | 1/57 | 0/31 |
| PyrexiaGeneral disorders | 4/114 | 2/57 | 1/31 |
| Septic ShockInfections and infestations | 1/114 | 0/57 | 1/31 |
| Femur FractureInjury, poisoning and procedural complications | 0/114 | 0/57 | 1/31 |
| Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/114 | 0/57 | 1/31 |
| AnaemiaBlood and lymphatic system disorders | 3/114 | 0/57 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 3/114 | 0/57 | 0/31 |
| FatigueGeneral disorders | 3/114 | 0/57 | 0/31 |
| Event | Cisplatin and Cetuximab | Cisplatin | Cisplatin Alone Switched to Cetuximab |
|---|---|---|---|
| NauseaGastrointestinal disorders | 73/114 | 37/57 | 8/31 |
| VomitingGastrointestinal disorders | 43/114 | 37/57 | 7/31 |
| FatigueGeneral disorders | 56/114 | 20/57 | 6/31 |
| RashSkin and subcutaneous tissue disorders | 56/114 | 1/57 | 5/31 |
| Decreased AppetiteMetabolism and nutrition disorders | 40/114 | 8/57 | 4/31 |
| Dermatitis AcneiformSkin and subcutaneous tissue disorders | 23/114 | 0/57 | 9/31 |
| NeutropeniaBlood and lymphatic system disorders | 33/114 | 10/57 | 3/31 |
| ConstipationGastrointestinal disorders | 27/114 | 16/57 | 5/31 |
| Dry SkinSkin and subcutaneous tissue disorders | 29/114 | 1/57 | 2/31 |
| AstheniaGeneral disorders | 26/114 | 14/57 | 3/31 |
| Age, Continuous(years) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Mean | 52.9 ± 12.53 | 51.7 ± 10.67 | 52.5 ± 11.92 |
| Age, Customized(participants) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| < 65 years | 93 | 51 | 144 |
| >= 65 years | 22 | 7 | 29 |
| Sex: Female, Male(Participants) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Female | 115 | 58 | 173 |
| Male | 0 | 0 | 0 |
| Naturally post menopausal participants(participants) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Yes | 64 | 36 | 100 |
| No | 51 | 22 | 73 |
| Duration of breast cancer from primary tumor diagnosis to informed consent(months) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Median | 19.2 (0.0 to 350.0) | 17.3 (0.0 to 199.0) | 18.7 (0.0 to 350.0) |
| Participants categorized by site of metastasis(participants) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Lung | 64 | 26 | 90 |
| Lymph nodes (by medical review) | 49 | 22 | 71 |
| Bone | 37 | 20 | 57 |
| Liver | 36 | 17 | 53 |
| Skin | 20 | 8 | 28 |
| Other | 15 | 8 | 23 |
| Duration of metastatic breast cancer from metastasis to informed consent(months) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Median | 0.9 (0.0 to 56.0) | 0.8 (0.0 to 41.0) | 0.9 (0.0 to 56.0) |
| Duration from initial breast cancer diagnosis to date of metastasis(months) | Cisplatin and Cetuximab | Cisplatin | Total |
|---|---|---|---|
| Median | 15.7 (0.0 to 349.0) | 15.4 (-4.0 to 199.0) | 15.5 (-4.0 to 349.0) |
The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Cisplatin
Merck KGaA, Darmstadt, Germany →